INCR News and Press, Intercure Ltd. From 11/21/23

Intercure Ltd. (INCR) is expected to report for Q3 2023

2023-10-31 17:29:35 ET More on InterCure InterCure: Leader In Israel's Growing Medical Cannabis Market InterCure says one of its sites designated as closed military area by Israeli authorities Seeking Alpha’s Quant Rating on InterCure Historical earnin...

NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company&...

2023-10-17 17:17:12 ET More on InterCure InterCure: Leader In Israel's Growing Medical Cannabis Market Seeking Alpha’s Quant Rating on InterCure Historical earnings data for InterCure Financial information for InterCure For further details see:...

NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the security ...

2023-10-09 13:00:03 ET More on InMode, Nano-X, etc. Full Of Potential Red Flags: Breaking Down Nano-X Imaging Nano-X Imaging: Cash Burn Makes It A Hold InMode: Bullish Support Failed To Materialize War between Israel and Hamas pushes U.S.-traded Israeli stock...

2023-10-09 08:23:30 ET More on InMode, Mirati Therapeutics, etc. InMode: Bullish Support Failed To Materialize InMode: Strong Net Cash Position Sets The Stage For Opportunistic Buybacks InMode: Be Greedy When Others Are Fearful Bristol-Myers Squibb to acquire...

2023-08-31 23:11:37 ET More on InterCure InterCure: Leader In Israel's Growing Medical Cannabis Market InterCure, Cookies launch flagship retail location in Austria InterCure reports 29% sequential growth in revenue: Q4 Results InterCure, Clever Leaves enter ...

Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023 Annualized revenue run rate of NIS 41 7 million ($ 149 million) Adjusted EBITDA 2 of NIS 30 mill...

2023-08-28 13:15:00 ET Summary Investing in cannabis stocks has seen a series of mistakes, including underestimating growth deceleration and overestimating synergies from M&A. Alan Brochstein and Julian Lin on why companies in the cannabis industry should be more aggressive in...